Dixyrazine

Structural formula
	Structural formula without stereochemistry
General
Non-proprietary name	Dixyrazine
Molecular formula	C 24 H 33 N 3 O 2 S; C 24 H 33 N 3 O 2 S 2 HCl ( dihydrochloride );
Brief description	White dust
External identifiers / databases
EC number	219-591-3
ECHA InfoCard	100,017,811
PubChem	17182
Wikidata	Q2759774
Drug information
ATC code	N05 AB01
properties
Molar mass	427.60 g mol −1
Physical state	firmly
Melting point	67-71 ° C
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling ; no classification available
Toxicological data	400 mg kg −1 ( LD 50 , rat , oral ) ; 37.5 mg kg −1 ( LD 50 , rat , iv ) ;
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Dixyrazine is the abbreviation for a neuroleptic antihistamine that was introduced in Germany in 1969 under the brand name Esucos.

A 1989 study reported the effectiveness of intravenous administration of dixyrazine in combination with betamethasone in controlling nausea and vomiting caused by anticancer drugs such as doxorubicin and cisplatin . Dixyrazine has also been shown to be effective in controlling the same symptoms in the postoperative period of laparoscopic cholecystectomy and after major surgery in children.

Individual evidence

↑ ^a ^b ^c ^d ^e Entry on dixyrazine. In: Römpp Online . Georg Thieme Verlag, accessed on June 27, 2014.
↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
↑ Technical information: Esucos 25 mg tablets .
↑ B Sorbe, C Hallen: Betamethasone-dixyrazine versus betamethasone-metoclopramide as antiemetic treatment of cisplatin-doxorubicin-induced nausea in ovarian carcinoma patients . In: Eur J Gynaecol Oncol . 1991, 12, pp. 31-37, PMID 2050157 .
↑ C. Glaser, C Sitzwohl, T Wallner, A lark, P Marhofer, I Schindler: Dixyrazine for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy . In: Acta Anaesthesiol Scand . 2004, 48, pp. 1287-1291, PMID 15504190 .
↑ E Kokinsky, E Thornberg, K Nilsson, LE Larsson: Postoperative nausea and vomiting in children using patient-controlled analgesia: the effect of prophylactic intravenous dixyrazine . In: Acta Anaesthesiol Scand . 1999, 43, pp. 191-195, PMID 10027027 .

[roempp-1] Entry on dixyrazine. In: Römpp Online . Georg Thieme Verlag, accessed on June 27, 2014.

[NV-2] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[3] Technical information: Esucos 25 mg tablets .

[4] B Sorbe, C Hallen: Betamethasone-dixyrazine versus betamethasone-metoclopramide as antiemetic treatment of cisplatin-doxorubicin-induced nausea in ovarian carcinoma patients . In: Eur J Gynaecol Oncol . 1991, 12, pp. 31-37, PMID 2050157 .

[5] C. Glaser, C Sitzwohl, T Wallner, A lark, P Marhofer, I Schindler: Dixyrazine for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy . In: Acta Anaesthesiol Scand . 2004, 48, pp. 1287-1291, PMID 15504190 .

[6] E Kokinsky, E Thornberg, K Nilsson, LE Larsson: Postoperative nausea and vomiting in children using patient-controlled analgesia: the effect of prophylactic intravenous dixyrazine . In: Acta Anaesthesiol Scand . 1999, 43, pp. 191-195, PMID 10027027 .